1. P247 Lumacaftor/ivacaftor is associated with high discontinuation rates in patients with baseline severe lung function but also benefits in those who tolerate therapy. (15th November 2017) Authors: Wareham, JM; Webb, KA; Jones, AM; Brennan, AL; Bright-Thomas, RJ; Horsley, AR; Barry, PJ Journal: Thorax Issue: Volume 72(2017)Supplement 3 Page Start: A218 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗